Moderna Slides as Full Melanoma Vaccine Results Follow Data Leak
The phase 3 results showed lower recurrence and spread risks with the personalized vaccine and Keytruda, but Moderna shares fell sharply.
Key takeaways
- The vaccine and Keytruda reduced recurrence or death risk by 42% versus Keytruda alone.
- Moderna shares were down 25.02% from the previous close as of 18:56 UTC Thursday.
Moderna shares fell sharply Thursday after partial data leaked from a closely watched cancer vaccine trial. Full results released later showed the personalized vaccine, intismeran autogene, plus Merck’s Keytruda reduced the risk of recurrence or death in certain melanoma patients by 42% compared with Keytruda alone.
The combination also cut the risk of cancer spreading to distant parts of the body or death by 38% versus Keytruda alone. The phase 3 results were scheduled for presentation at a European Society for Medical Oncology conference this weekend.
As of 18:56 UTC Thursday, Moderna shares traded at $184.32, down 25.02% from the previous close. Merck shares were down 0.66% at $148.89.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.
